← Eichor
Study identifier: NCT07063862 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)

Condition: Psychological Distress  ·  Sponsor: Bruyère Health Research Institute.

PhasePhase 3
Planned participants120
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

About 30-50% of patients with advanced illness experience depression, anxiety, or decreased sense of purpose and autonomy. Together, these are called psychological distress. Treatment options such as medication and therapy are available; however, they do not always work and can be time-consuming and expensive. We need treatments that work well, quickly, and can be available to all patients with advanced illness who have psychological distress. Psilocybin, a psychedelic medication (commonly called 'magic mushrooms') works well for improving psychological distress in people with cancer or chronic illness when given in high doses with specific forms of therapy. However, psilocybin has not been well-studied among people with advanced illness, and there are concerns about safety and side effects in people approaching the end of life. However, reports on psilocybin microdosing, which involves taking small doses that do not cause hallucinations and do not require therapy, suggest that this may be effective, safer, and more acceptable for people with advanced illness. We recently completed a small study of psilocybin microdosing. Our results showed psilocybin microdose improved psychological distress in most participants with advanced illness, without serious side effects. Our next step is to do a randomized clinical trial where some patients receive psilocybin microdose and some receive placebo (a drug that contains no medicinal ingredients). By comparing these two groups, we can …

This description comes directly from the study's public registry record.

Talk to the study team

James Downar, MDCM, MHSc  ·  613-562-6262  ·  jdownar@toh.ca

Julie Lapenskie, MSc  ·  613-562-6262  ·  jlapenskie@bruyere.org

Always discuss trial participation with your own doctor first.

Locations (7)

William Osler Health SystemBrampton, Ontario, CanadaNot Yet Recruiting
Providence Care HospitalKingston, Ontario, CanadaRecruiting
St. Joseph's HealthcareLondon, Ontario, CanadaNot Yet Recruiting
South Lake Regional Health CentreNewmarket, Ontario, CanadaRecruiting
Bruyere HealthOttawa, Ontario, CanadaRecruiting
The Ottawa HospitalOttawa, Ontario, CanadaNot Yet Recruiting
McGill University Health CentreMontreal, Quebec, CanadaNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07063862